Society Position Statements on Bio-Identical Hormones-Misinformation Leads to a Dilemma in Women’s Health
Abstract
:1. History
2. Published Society Opinions
“Not only is evidence lacking to support superiority claims of compounded bioidentical hormones over conventional menopausal hormone therapy, but these claims also pose the additional risks of variable purity and potency and lack efficacy and safety data.”
“Compounded hormone therapies are prepared by a compounding pharmacist using a provider’s prescription and may combine multiple hormones (estradiol, estrone, estriol, dehydroepiandrosterone [DHEA], testosterone, progesterone), use untested, unapproved combinations or formulations, or be administered in nonstandard (untested) routes such as subdermal implants, pellets, or troches.”
“Compounded HT has been prescribed or dosed on the basis of salivary hormone testing; however, salivary testing for HT is considered unreliable because of differences in hormone pharmacokinetics and absorption, diurnal variation, and interindividual and intraindividual variability.”
“Prescribers should only consider compounded HT if women cannot tolerate a government-approved therapy for reasons such as allergies to ingredients or for a dose or formulation not currently available in government-approved therapies. With interim guidance on compounding safety and quality control from FDA, quality control of compounded HT may improve.”
“Compounded bioidentical HT presents safety concerns such as minimal government regulation and monitoring, overdosing or underdosing, presence of impurities or lack of sterility, lack of scientific efficacy and safety data, and lack of a label outlining risks.”
3. Compounding
4. Women’s Health and Wellness
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Rossouw, J.E.; Anderson, G.L.; Prentice, R.L.; LaCroix, A.Z.; Kooperberg, C.; Stefanick, M.L.; Jackson, R.D.; Beresford, S.A.A.; Howard, B.V.; Johnson, K.C.; et al. Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results from the Women’s Health Initiative Randomized Controlled Trial. Writing Group for the Women’s Health Initiative Investigators. JAMA 2002, 288, 321–333. [Google Scholar]
- Sherwin, B.B.; Morrie, M.G. Effects of parenteral administration of estrogen and androgen on plasma hormone levels and hot flushes in the surgical menopause. Am. J. Obstet. Gynecol. 1984, 148, 552–557. [Google Scholar] [CrossRef]
- The Truth About Hormones: Hormone Replacement Therapy Is Riskier Than Advertised. Time Magazine, 22 July 2002.
- Sarrel, P.M.; Njike, V.Y.; Vinante, V.; Katz, D.L. The Mortality Toll of Estrogen Avoidance: An Analysis of Excess Deaths Among Hysterectomized Women Aged 50 to 59 Years. Am. J. Public Health 2013, 103, 1583–1588. [Google Scholar] [CrossRef]
- ACOG. ACOG Committee Opinion #322: Compounded Bioidentical Hormones. Obstet. Gynecol. 2005, 106, 1139–1140. [Google Scholar]
- ACOG. ACOG Committee Opinion No. 387 November 2007: Pharmaceutical Compounding. Obstet. Gynecol. 2007, 110, 1213–1214. [Google Scholar] [CrossRef] [PubMed]
- ACOG. Committee opinion No. 532: Compounded bioidentical menopausal hormone therapy. Obstet. Gynecol. 2012, 120, 411–415. [Google Scholar] [CrossRef]
- The North American Menopause Society. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause 2017, 24, 728–753. [Google Scholar] [CrossRef]
- Facility Definition under Section 503B of the Federal Food, Drug, and Cosmetic Act; Guidance for Industry; Availability. Available online: https://www.federalregister.gov/d/2018-10046 (accessed on 5 November 2018).
- Donovitz, G.; Schwartz, E.; Miller, C.; Barber, M.; Comite, F.; Janson, K.; Leake, J.; Lee, E.; Life, J.; Martinez, L.; et al. Testosterone Insufficiency and Treatment in Women: International Expert Consensus. MSP Med. Salud Publica 2019. Available online: https://medicinaysaludpublica.com/noticias/general/testosterone-insufficiency-and-treatment-in-women-international-expert-consensus/5093 (accessed on 5 November 2018).
- Glaser, R.; York, A.E.; Dimitrakakis, C. Beneficial Effects of Testosterone Therapy in Women Measured by the Validated Menopause Rating Scale (MRS). Maturitas 2011, 68, 355–361. [Google Scholar] [CrossRef] [PubMed]
- Cardozo, L.; Gibb, D.M.; Tuck, S.M.; Thom, M.H.; Studd, J.W.; Cooper, D.J. The Effects of Subcutaneous Hormone Implants During the Climacteric. Maturitas 1984, 5, 177–184. [Google Scholar] [CrossRef]
- Shifren, J.; Davis, S.R. Androgens in Postmenopausal Women: A Review. Menopause 2017, 24, 970–979. [Google Scholar] [CrossRef] [PubMed]
- Greenblatt, R.B.; Suran, R.R. Indications for Hormonal Pellets in The Therapy of Endocrine and Genetic Disorders. Am. J. Obstet. Gynecol. 1949, 57, 294–301. [Google Scholar] [CrossRef]
- van Winden, L.J.; van Tellingen, O.; van Rossum, H.H. Serum Testosterone by Liquid Chromatography Tandem Mass Spectrometry for Routine Clinical Diagnostics. In Clinical Metabolomics. Methods in Molecular Biology; Giera, M., Ed.; Humana Press: New York, NY, USA, 2018. [Google Scholar]
- American College of Obstetricians and Gynecologists Committee on Gynecologic Practice; American Society for Reproductive Medicine Practice Committee. Compounded Bioidentical Menopausal Hormone Therapy. Fertil. Steril. 2012, 98, 308–312. [Google Scholar] [CrossRef] [PubMed]
- Silverman, D.H.; Geist, C.L.; Kenna, H.A.; Williams, K.; Wroolie, T.; Powers, B.; Brooks, J.; Rasgon, N.L. Differences in regional brain metabolism associated with specific formulations of hormone therapy in postmenopausal women at risk for AD. Psychoneuroendocrinology 2011, 36, 502–513. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Canonico, M.; Oger, E.; Plu-Bureau, G.; Conard, J.; Meyer, G.; Lévesque, H.; Trillot, N.; Barrellier, M.T.; Wahl, D.; Emmerich, J.; et al. Hormone therapy and venous thromboembolism among postmenopausal women: Impact of the route of estrogen administration and progestogens: The ESTHER study. Circulation 2007, 115, 840–845. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Glaser, R.; York, A.E.; Dimitrakakis, C. Incidence of Invasive Breast Cancer in Women Treated with Testosterone Implants: A Prospective 10-year Cohort Study. BMC Cancer 2019, 19, 271. [Google Scholar] [CrossRef] [PubMed]
- Donovitz, G.; Cotten, M. Breast Cancer Incidence Reduction in Women Treated with Subcutaneous Testosterone: Testosterone Therapy and Breast Cancer Incidence Study. Eur. J. Breast Health 2021, 17, 150–156. [Google Scholar] [CrossRef] [PubMed]
- Donovitz, G.S. Low complication rates of testosterone and estradiol implants for androgen and estrogen replacement therapy in over 1 million procedures. Therapeutic Advances in Endocrinology and Metabolism. Ther. Adv. Endocrinol. Metab. 2021, 12. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Donovitz, G.S. Society Position Statements on Bio-Identical Hormones-Misinformation Leads to a Dilemma in Women’s Health. Healthcare 2021, 9, 782. https://doi.org/10.3390/healthcare9070782
Donovitz GS. Society Position Statements on Bio-Identical Hormones-Misinformation Leads to a Dilemma in Women’s Health. Healthcare. 2021; 9(7):782. https://doi.org/10.3390/healthcare9070782
Chicago/Turabian StyleDonovitz, Gary S. 2021. "Society Position Statements on Bio-Identical Hormones-Misinformation Leads to a Dilemma in Women’s Health" Healthcare 9, no. 7: 782. https://doi.org/10.3390/healthcare9070782